Advertisement

Topics

Novartis eye drug works at less frequent dosing than rival's

06:39 EDT 20 Jun 2017 | Topix

FILE PHOTO: The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland, January 25, 2017. Novartis eye drug RTH258 works as well as a rival product from Regeneron and at less frequent dosing in clinical trials, the Swiss drugmaker said on Tuesday, boosting its shares.

Original Article: Novartis eye drug works at less frequent dosing than rival's

NEXT ARTICLE

More From BioPortfolio on "Novartis eye drug works at less frequent dosing than rival's"

Advertisement
Quick Search
Advertisement
Advertisement